> ## Content Index > Fetch the complete content index at: https://www.moatmarginresearch.com/llms.txt > Use this file to discover other available public pages before exploring further. # Indegene Moat Analysis: Score & Risks - URL: https://www.moatmarginresearch.com/indegene-moat/ - Published: 2026-08-16T16:50:47.000Z - Updated: 2026-08-22T05:13:29.000Z - Author: A K Karthikeyan - Tags: First-pass note, Coverage Moat Note · First-pass ## Indegene Ltd. A first-pass moat teardown of Indegene Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it. **Moat & Margin**16 Aug 2026 First-pass · \~3 min 4.86 / 10 NARROWProcess/Data-led First-pass narrow read — primary edge in Switching Costs. Provisional, single-pass evidence. Provisional score · subject to modification based on new evidence Indegene Ltd. scores **4.86** on MoatSCORE 6.0 — a narrow moat in Pharma. This is a **first-pass note**: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued. The teardown ## Seven dimensions of moat Ordered by contribution. Each dimension carries a verified filing quote, graded **\[M\]** mechanism or **\[O\]** outcome. D2Switching Costs5.5 O · Outcome✓ Verified verbatim “Overall, the renewals were stable in value terms with these Gen AI-led forays expected to yield positive results as volumes for the new deliverables included in our work orders ramp up through the period.” **Indegene Ltd.** · Earnings Call · p.7 1 quote extracted here — not one mechanism-class. The evidence is outcome-only. D3Cost Advantage5.5 No verified filing quote surfaced for this dimension in the first-pass evidence sweep. D4Price Discretion5.5 M · Mechanism✓ Verified verbatim “coupled with our predominant managed-outcome pricing model” **Indegene Ltd.** · Earnings Call · p.5 D5Intangible Assets5.5 M · Mechanism✓ Verified verbatim “First-to-file economics intensifying — each molecule carries >$2B R&D risk” **Indegene Ltd.** · Investor Presentation · p.10 D1Network Effects4.8 M · Mechanism✓ Verified verbatim “the Company operates in more than 80 markets through a global delivery network spanning 17+ delivery and operational centers across 11 countries” **Indegene Ltd.** · Annual Report · p.50 D6Efficient Scale4.8 M · Mechanism✓ Verified verbatim “The customer concentration itself is about 80% for the top 20 customers, about 60% top 10 customers.” **Indegene Ltd.** · Earnings Call · p.8 D7Counter-PositioningExcluded— Excluded for this archetype. D8Ungoverned RiskUnscored · Layer 2.5 D8 rating: **ADEQUATE**. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed. The barrier gate ## The barrier gate — first-pass Replication — can a rival copy it?5.0 How hard it is for a rival to copy the edge (first-pass estimate). Bypass — can a rival route around it?5.0 How easily a rival can route around the edge (first-pass estimate). Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate. What would change our mind 1. **Deep two-pass review.** This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read. 2. **The barrier gate.** A firmer replication or bypass estimate is the most likely thing to shift the band. 3. **Adverse events.** Any governance, regulatory or funding shock captured in D8 could re-rate the fade window. First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser. **Where this note fits.** This company is one of **509 Indian companies** we have scored for moat durability — 370 narrow, 126 narrow-trending-wide, none wide. Every score, dimension by dimension, is free in the [Moat Screener](https://www.moatmarginresearch.com/moat-screener/).